FDA
approval
· 2022-05-25
FDA Approved: YUPELRI — Supplemental Application (Viatris Specialty LLC)
Summary
FDA approved a supplemental application for YUPELRI (revefenacin) from Viatris Specialty LLC.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for YUPELRI (REVEFENACIN)